Fibroblast growth factor in extremities

Michiko Tanaka, Yoshikazu Yonemitsu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Fibroblast growth factor (FGF) is recognized as one of the major angiogenic factors. Among the FGF family members, FGF-1 (acidic fibroblast growth factor, aFGF) and FGF-2 (basic fibroblast growth factor, bFGF) have been extensively studied at both preclinical and clinical stages for applications in therapeutic angiogenesis. In vivo studies have reported various synergistic effects of FGF-2, and gene therapy has achieved promising results in early preclinical studies. However, few clinical trials have been conducted. In this chapter, we provide an overview and future perspectives of the progression of research into angiogenic gene therapy with FGF for peripheral artery disease. The focus of a new gene transfer vector based on a non-transmissible recombinant Sendai virus that expresses the human FGF-2 gene is also introduced as a frontier of therapeutic angiogenesis in this field.

Original languageEnglish
Title of host publicationTherapeutic Angiogenesis
PublisherSpringer Singapore
Pages145-158
Number of pages14
ISBN (Electronic)9789811027444
ISBN (Print)9789811027437
DOIs
Publication statusPublished - Jul 11 2017

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Engineering(all)
  • Computer Science(all)

Cite this

Tanaka, M., & Yonemitsu, Y. (2017). Fibroblast growth factor in extremities. In Therapeutic Angiogenesis (pp. 145-158). Springer Singapore. https://doi.org/10.1007/978-981-10-2744-4_10